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ABSTRACT
A mesenchymal-epithelial
cell interaction
exists in the testis between the Sertoli
cells that form the seminiferous
tubule
and the
mesenchymal-derived
peritubular
myoid cells that surround
the tubule. Analysis
of the mesenchymal-epithelial
interactions
between
these cells revealed
the local production
of a mesenchymal
factor,
PModS. PModS modulates
the differentiated
functions
of Sertoli cells
in uitro, including
stimulation
of the iron-binding
protein
transferrin
(Tf). Previous
results
have indicated
that PModS-induced
Tf gene
expression
involves
the activation
of immediate
early genes. One of
the immediate
early genes was identified
as c-fos. The importance
of
c-fos was demonstrated
in the current
study when a c-fos antisense
oligonucleotide
was found to inhibit
the ability of PModS to induce the
expression
of a Tf promoter-chloramphenicol
acetyltransferase
(CAT)
construct.
The regulation
of c-fos by PModS
was investigated
with
various
CAT constructs
containing
segments
of the c-fos promoter,
such as the serum
response
element
(SRE),
.&-inducible
element
(SIE),
CAMP response
element
(CRE),
and phorbol
ester/TPA
response element
(TRE), transfected
into cultured
Sertoli cells. PModS
has no effect on CAMP response
element-CAT
or TRE-CAT,
suggesting that PModS does not act through
stimulation
of CAMP and protein
kinase C pathways.
PModS was found to activate
the c-fos SRE-CAT
construct
and the SIE-CAT
construct.
A construct
containing
both
SIE and SRE was stimulated
to the same degree as either
element
alone. Gel mobility
shift assays using nuclear
extracts
from PModSstimulated
Sertoli
cells and a radiolabeled
SRE oligonucleotide
resulted in retarded
mobility
of a DNA-protein
complex.
A gel shift with
a SRE oligonucleotide
containing
an ETS domain resulted
in a unique
shift only detected
in PModS-stimulated
cells. PModS
also promoted
a gel shift with the SIE that is adjacent
to the SRE on the c-fos
promoter.
The data imply that PModS can activate
the c-fos promoter
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through
the SRE and SIE. PModS caused a labeled activating
protein
1 (APl)
oligonucleotide
to form a DNA-protein
complex,
indicating
activation
of the c-fos gene and binding
of the c-fosljun
complex.
To
study the downstream
regulation
of Sertoli
cell differentiation,
Tf
gene expression
was examined.
CAT constructs
containing
deletion
mutants
of a 3-kilobase
(kb) mouse Tf promoter
were used. When
transfected
into Sertoli cells the 581-base
pair Tf minimal
promoter
had only a slight response
to PModS,
but was activated
by FSH. The
2.6-kb Tf promoter
construct
responded
to PModS. This response was
greater
than that observed
with the 1.6- or 3-kb Tf promoter
constructs.
These results suggest that an upstream
enhancer
located in
the Tf promoter
between
-2.6 and -1.6 kb is responsive
to PModS.
Gel retardation
assays with two restriction
fragments,
designated
SE1 and SE2, located at -2.4 and -1.9 kb, respectively,
on the Tf
promoter
showed a retarded
complex
with PModS-stimulated
Sertoli
cell nuclear
extracts.
No other restriction
enzyme
fragment
of the Tf
promoter
was found to cause a gel shift. These SE1 and SE2 domains
are in a region with apparent
enhancer
activity
and were found not
to contain
a c-fosljun API-binding
site. An immunoblot
with c-fos
antibodies
of the SE1 and SE2 gel shift indicated
the absence of c-fos
in the DNA-protein
complex.
Therefore,
PModS-responsive
cis-elements on the Tf promoter
were identified
(i.e. SE1 and SE2) that do
not appear
to involve
a direct activation
by c-fos at APl, but involve
an intermediate
c-fos-regulated transcription factor(s). The findings
suggest that PModS
acts through
activation
of the SRE and SIE to

induce the immediate

early gene, c-fos, which then influences

an

intermediate
transcription
factor(s)
that regulates
downstream
Sertoli cell differentiated
functions,
such as Tf expression.
These studies
have initiated
an investigation
of the transcriptional
regulation
of
Sertoli cell differentiation.
(Endocrinology 136: 3046-3053,
1995)

the local production
of a mesenchymal
factor, termed PModS
(1,2). The testicular paracrine factor, PModS, is produced
by
the peritubular
myoid cells under androgen
control and
modulates
Sertoli cell differentiated
functions in vitro (1, 2).
Among these differentiated
functions is the synthesis of the
iron-binding
protein, transferrin
(Tf) (3,4). Tf expression has
been used as a marker of Sertoli cell differentiation
during
pubertal
development
(4). To investigate
the pharmacology
of PModS, several common
signal transduction
pathways
were analyzed. PModS was found to have no effect on CAMP
levels (4) or on calcium mobilization
or phosphoinositide
metabolism
(5). Although
PModS
was found to elevate
cGMP, cGMP does not mediate the actions of PModS (5).
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Treatment of Sertoli cells with the tyrosine phosphorylation
inhibitor, genistein, suppresses PModS-stimulated
Tf production (5). Therefore, the actions of PModS on Sertoli cells
appear to be in part through an activation of tyrosine kinasefs). Regulation of Sertoli cell differentiation
by PModS
on a molecular level has also been investigated. An inhibitor
of translation,
cycloheximide,
was used to determine
whether PModS could directly stimulate Tf messenger RNA
(m&WA) expression or whether intermediate protein synthesis was involved. Cycloheximide
inhibited PModS-induced Tf mRNA synthesis, indicating that activation of immediate early genes is required for stimulation
of Tf
expression (6). Northern analysis of potential immediate
early genes demonstrated
that PModS stimulates c-fos
mRNA synthesis, but has no effect on two other nuclear
proteins c-jun and C/EBP. The protein c-fos is a protooncogene that is transiently stimulated by a variety of mitogens
and differentiation
factors (7). Time-course data show that
c-fos mRNA levels increase within minutes after PModS
treatment and subsequently decline to basal levels after 2 h.
In contrast, PModS-induced
increases in Tf mRNA do not
occur until 2 h, then peak at approximately
12 h, and are
maintained for up to 5 days in culture. Treatment of Sertoli
cells with a c-fos antisense oligonucleotide
partially suppresses PModS-enhanced Tf protein production (6). These
data indicate that c-fos is involved as an immediate early gene
in response to PModS. The current study was designed to
analyze PModS activation of the c-fos promoter and relate
this to the previous data on signal transduction and Sertoli
cell differentiation. Activation of the Tf promoter was investigated as a downstream
event involved in Sertoli cell
differentiation.

Materials
Cell preparation

and

Methods

and culture

Sertoli cells were isolated
from the testis of 20-day-old
rats by sequential enzymatic
digestion
(8), with a modified
procedure
described
by Tung et al. (9). Decapsulated
testicular
fragments
were digested first
with trypsin
(1.5 mg/ml;
Gibco-BRL,
Gaithersburg,
MD) to remove
the
interstitial
cells and then with collagenase
(1 mg/ml
type I; Sigma
Chemical
Co., St. Louis, MO) and hyaluronidase
(1 mg/ml;
Sigma).
Sertoli cells were then plated under serum-free
conditions
in 24-well
Falcon plates at 1 X 106~cells/well.
Cells were maintained
in a 5% CO,
atmosuhere
in Ham’s F-12 medium
(Gibco-BRL)
at 32 C. Sertoli cell
cultures were treated as described
in Results, after 48 h of culture
and
transfection.
Cultures
were treated with FSH (100 rig/ml;
ovine FSH-16,
National
Pituitary
Agency),
(Bu),cAMP
(1 mM1, 10% calf serum,
or
greater
than maximally
effective
concentrations
of PModS(S300)
(25 Kg/ml)
or PModS(C4)
(25 rig/ml).
Peritubular
cells were obtained
from the collagenase
digestion
supernatant,
as described by Skinner et al. (21, after the tubule segments had
sedimented.
Peritubular
cells were plated in Ham’s F-12 medium
containing 10% calf serum and grown
to confluence.
Cells were then subcultured
and plated at 25% confluence.
When subcultured
cells were
confluent,
they were washed with serum-free
medium.
The cells were
subsequently
cultured
in serum-free
medium
for up to 4 weeks with
48- to 72-h medium
collections.
Freshly
collected
serum-free
conditioned
medium
from the peritubular cells was treated with phenylmethylsulfonylfluoride
(25 FM final
concentration)
and benzamidine
(0.1 mM final concentration)
and centrifuged
at 1000 X g for 15 min at 4 C to remove
cell debris. When
necessary,
medium
was stored at -20 C. Conditioned
medium
was
I
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concentrated
loo-fold
by ultrafiltration
with an Amicon system (Amicon
Corp., Lexington,
MA) and a 3000 mol wt exclusion
limit membrane.

PModS

preparation

PModS was obtained
from concentrated
peritubular
cell-conditioned
medium,
as previously
described
(2). An ammonium
sulfate precipitate
of concentrated
conditioned
medium
was applied
to a size-exclusion
Sephacryl
S300 column
(Pharmacia,
South San Francisco,
CA). The active peak of the 5300, determined
by bioassay of Sertoli cell Tf production, was collected
and applied
to a chromatofocusing
column
(Pharmacia). The pH 5.7-6.8
pool was applied
to a 1 X 15.cm heparinSepharose
affinity
column.
Eluted
proteins
were
applied
to two
successive C4 reverse phase columns
(Vydac, Hesperia,
CA) and eluted
with a linear gradient-from
25-60%
acetonitrile.
The partially
purified
PModS 5300 pool, termed
PModS(S300),
and the more highly purified
PModS(C4)
fraction,
termed
I’ModS(C4),
were stored at -70 C before
use in the presence of 1 mg/ml
BSA.

Reporter

gene constructs

c-Fos promoter.
The chloramphenicol
acetyltransferase
(CAT) reporter
plasmids
(PBL-CAT2)
with the thymidine
kinase minimal
promoter
(10)
containing
either the CAMP response element (CRE) [120-base pair (bp)
5’-flanking
sequence from the transcriptional
start site of the human c-fos
promoter
with a 5’-TGACGTTT-3’
sequence at -60 bpl, TPA/activating
protein
1 (APl) response element (TRE; 5’-TGCGTCA-3’1,
or the serum
response
element (SRE; 5’-CAGGATGTCCATATTAGGACATC-3’)
sequences of the c-fos promoter
were generated;
the entire c-fos promoter
was generously
provided
by Dr. Jeff Holt (Vanderbilt
University,
Nashville, TN). The sis-inducible
element
(SIE)-CAT
reporter
plasmid
was
constructed
by cloning
a synthetic
15-bp oligonucleotide
(CATTTCCCGTAAATC)
(11) with Hind111 and SphI sites on either ends into
PBLCAT2
plasmid.
The SIE/SRE construct
was prepared
by cloning the
15-bp SIE oligo into HindIII/SphI
sites of the SRE-CAT
plasmid.
Tfpromoter.
The CAT reporter
plasmid
containing
-581 bp (PUC8 CAT)
and the human
GH reporter
plasmid
containing
-3.0-kilobase
(kb)
sequences
of the mouse Tf (mTfl promoter
(12) were generously
provided
by Dr. G. Stanley
McKnight
(University
of Washington,
Seattle, WA). The CAT reporter
plasmids
containing
-3.O-kb
mTf promoter and its deletions
were constructed
as follows.
1) The 3.0-kb mTf
CAT construct
was made by ligating
a -3.O-kb
BarnHI-BumHI
digest to
the BamHI site in PGL2-CAT
plasmid
(Promega).
2) The 2-kb upstream
HindIII-Hind111
fragment
in the 3-kb mTf promoter
was ligated in the
Hind111 site of -581-bp
mTf-CAT
to obtain the 2.6-kb mTf-CAT
plasmid.
3) The -1.6-kb
mTf CAT plasmid
was derived
from the -3.O-kb
mTf
CAT (no. 1 above) by digesting
out the upstream
- 1.4-kb PstI fragment.
4) To prepare
the upstream
l-kb mTf-CAT
(I-kb Tf-Tk-CAT),
the 3-kb
mTf plasmid
was digested with HindIII-PstI.
The I-kb fragment
(1.6-2.6
kb) was then cloned into a I’BL-CAT2
plasmid.
Constructs
for each of the plasmids
that did not contain the specific
response element or promoter
fragment
(i.e. promoterless
plasmid)
were
also generated.
In all cases, experiments
were performed
to examine the
actions of various
treatments
on these promoterless
plasmids.
As discussed in Results, these promoterless
plasmids
generally
did not respond
to the treatments.
If a small response was observed,
the data are shown
in the figures or stated in Results.

Transfection
Sertoli cells, cultured
for 48 h, were transfected
with a reporter
gene
construct
by the calcium phosphate
method coupled with hyperosmotic
shock (10% glycerol),
as previously
described
(131. Cells were treated 2
h after transfection,
and unless otherwise
stated, CAT activity
was
determined
after 48 h in culture.

CAT assay
Assay of CAT activity
was performed
as follows.
Medium
was removed
from the wells, and the cells were washed once with PBS. One
hundred
microliters
of 1 X cell lysis buffer
(Promega
Corp.,
Mad-
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ison, WI) were added to each well and incubated
for 15 min at room
temperature.
The wells were then scraped, and the buffer was collected
in 1.5-ml microfuge
tubes. Tubes were heated to 65 C for 10 min to
inactivate
endogenous
acetylases and then spun at 12,000 X ,Q for 10 min
at 4 C to remove cell debris. An aliquot of c&l extract (54 PlFwas mixed
with 65 ~10.25 M Tris (pH 8.0), 25 pg n-butyryl
coenzyme
A (5 mg/ml;
Sigma),
and 0.1 PCi [‘4C]chloramphenicol
(0.1 &i/PI;
ICN, Costa
Mesa, CA) and incubated
overnight
at 37 C. The mixture
was extracted
once with 300 ul xvlene and back-extracted
with 100 ~10.25 M Tris (PH
8.0). A 200-ml &iq;ot
of the organic phase was counted in a scintilladon
counter
to determine
the relative
amount
of CAT activity.

OF SERTOLI

conditions
described
above, detection
formed
using the chemiluminescent
Arlington
Heights,
IL).

Statistical
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of the immune
ECL method

complex
(Amersham

1995
No 7

was perCorp.,

analysis

Each data point was converted
to a percentage
of the control value,
and the mean and SEM from multiple
experiments
were determined,
as
indicated
in the figure
legends.
Data were analyzed
by analysis
of
variance,
using the SPSS Statistical
Package (SI’SS, Chicago,
IL).

Results

Gel mobility shift assay
Gel shift assays were performed
with nuclear
extracts
of isolated
Sertoli cells. The Sertoli cells were isolated
as described
above and
cultured
in 137-mm petri dishes (Falcon Plastics, Oxnard,
CA). The cells
were treated after 48 h in culture either FSH, PModS(S300),
or 10% calf
serum. After 72 h, the cells were scraped off the petri dishes and washed
once with PBS. The nuclear extracts of these cells were then prepared
as
described
by Guillou et al. (14). The probes used in gel retardation
assays
were the SRE (5’-GGATGTCCATATTAGGACACATCTG-3’)
and the
ETS-SRE element
(SRE with 5’-CAGGAT
sequence)
of the c-fos promoter; the SIE (5’-CATITCCCGTAAATC-3’)
located 25 bp upstream
of
the c+s SRE (15), and API dimer
(5’-TTAGTCATGAGTCA-3’).
The
complementary
oligonucleotides
were 5’-end labeled with I~321’lATP
(150 /.&I/d;
New England
Nuclear
Corp., Boston, MA) using polynucleotide
kinase, annealed,
and subsequently
purified
on a 12% polyacrylamide
gel.
Restriction
fragments
of the mTf promoter
between
-581 bp and -3
kb were obtained
with a series of enzvmes.
including
PvuII. NarI. HPuI.
and PstI. Fifteen
approximately
2OOtbp fragments
“were isolated,
‘de:
phosphorylated,
and end labeled with [~32P]ATP
using polynucleotide
kinase. Of these fragments,
two gave a positive
gel shift. The restriction
fragments
SE1 (200 bp) and SE2 (180 bp) were located at -2.4 and -1.9
kb, respectively,
on the 3-kb mTf 5’-flanking
region. These two Tf promoter fragments
(i.e. SE1 and SEZ) were routinely
isolated, dephosphorylated,
and end labeled with [y-32P]ATP
for gel shift analysis.
The gel retardation
assay used was a modification
of the protocol
described by Garner and Rezvin (15). The final reaction volume
of 20 ~1
contained
0.5 ng 5’-end 32P-labeled
double stranded
probe, 100 ng sonicated salmon sperm DNA, 2 LLP. DNA duplex
poly(dI-dC)
(U.S. Biochemical Corp.,*Cleveland,
OF&-20
pg B’S& 20 ~M~HEPES (pH 8.0), 4
mM Tris (uH 7.9). 50 mM KCl. 600 ILM EDTA (uH 8.0). EGTA (DH 8.0).
500 PM &hioth&tol,
and 5 bg S&toli
cell &ear
proteins.
After in:
cubation
at room temperature
for 20 min, 5 ~1 of the reaction
were
electrophoretically
separated
on a 5% polyacrylamide
gel. The gel was
dried and autoradiozravhed.
For the competition
experiments,
a 500fold molar excess of\niabeled
oligonucle&ide
or res’triction
fragment
was added to the binding
reaction.

To confirm that c-fos is involved at a molecular level in
PModS stimulation of Tf, a CAT reporter gene construct
containing -2.6 kb of the Tf gene promoter was transiently
transfected into cultured Sertoli cells. Sertoli cells were isolated from 20-day-old rat testis and cultured under serumfree conditions unless otherwise stated. After transfection,
the cells were left untreated (control) or were treated with
FSH, a partially purified PModS preparation from a sizeexclusion column termed PModS(S300), a combination of
PModS(S300)
and the antisense
c-jos oligonucleotide
(S300+ANTI),
or a combination of PModS(S300) and the
sense c-fos oligonucleotide
(S300+SENSE) for 48 h before
analysis of the cell extracts for CAT activity. FSH, S300, and
S300+SENSE activated the Tf CAT construct (Fig. 1). A control promoterless plasmid (pCAT-basic) was slightly stimulated by PModS(S300) treatment. Treatment of the transfected cells with the antisense oligonucleotide
inhibited
PModS(S300)-induced
CAT activity (Fig. 1). These data confirm that c-fos is involved in PModS-stimulated
Tf gene expression.
c-Fos promoter analysis
To determine how PModS activates c-fos gene expression,
CAT reporter gene constructs containing different regulatory
0

250

% Control (CAT Activity)
500
750
1000

1250

1500

Control
pCAT-basic-S300

Antisense procedure
A c-jos antisense oligonucleotide,
3’-TACTACGGTGCA-5’,
pared and used, as previously
described
(16, 17). A c-jos
nucleotide
was prepared
for use as a negative
control.
Sertoli cells were treated with either the antisense or sense
PM) starting
8 h after transfection
and retreated
every 8 h
48 h before harvest of the cells for CAT assay.

Immunoblot

was presense oligoTransfected
oligomer
(4
for a total of

3
2
Ti
$
2
;:
x
u

procedure

A gel mobility
shift assay was electrophoretically
transferred
to a
polyvinylidone
difluoride
membrane
(Immobilon
Millipore,
South San
Francisco, CA) by electrophoresis
in Tris-glycine
buffer containing
20%
methanol.
The blot was then blocked with 3% nonfat milk [dissolved
in
50 mM Tris (pH 7.4), 150 mM NaCl, and 0.05% Nonidet
P-401 and
incubated
with a 1:5000 dilution
of antibody
to c-fos (Santa Cruz Biotechnology,
Santa Cruz, CA) for 2 h. After three washes (15 min each),
the blot was hybridized
with a secondary
antibody
(1:3000 dilution;
directed
against rabbit immunoglobulin
G) conjugated
to horseradish
peroxidase
for 1 h at room temperature.
After five washes under the

s300
S3OO+Sense
S’JOO+Anti
FSH

1. Regulation
of the 2.6-kb Tfpromoter-CAT
construct
in Sertoli
cells cultured
in the absence
(control;
C) or presence
of FSH,
PModS(S300),
PModS(S300)
and c-fos antisense
oligonucleotide
@3OO+ANTI),
and PModS(S300)
and c-fos senseoligonucleotide
(S300+SENSE).
The actions of PModS(S300)
on a control pCAT-basic
plasmid
are also presented.
Data are expressed
as a percentage
of the
control
and are presented
as the mean t SEM from three different
experiments
performed
in replicate.
***, Statistical
difference
from
S300 or SBOO+SENSE
(P < 0.01).
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elements of the c-jos promoter were generated, including the
CRE, TRE, SIE, and SRE. A schematic representation of the
locations of these elements within the c-fos promotor is
shown in Fig. 2A. These constructs were transiently transfected into cultured Sertoli cells. After transfection, the cells
were left untreated (control) or were treated with FSH, 10%
calf serum, (Bul,cAMP, PModS(S3001, or more highly purified PModS preparations from the C4 reverse phase column
termed PModS(C4) for 48 h. The CRE of the c-jos promoter
was activated by both FSH and (Bu),cAMP 400% above the
control level (P < 0.051, which demonstrated that the reporter
construct can be activated (data not shown). Treatment with
PModS(S300) did not increase CRE-CAT activity above the
control level (Fig. 2Bl. Treatment of the c-fosTRE-transfected
cells with FSH resulted in a 300% stimulation above the
control level (P < 0.051, which demonstrated that this reporter construct can be activated (data not shown). Treatment of the transfected Sertoli cells with PModS(S300) does
not stimulate the TRE construct (Fig. 28). A SRE construct
was used that included the 5’-flanking 5-bp ETS domain
ETS-SRE sequence of the c-fos promoter. Activation of the
c-fosSREconstruct was accomplished by treatment with 10%
calf serum as a positive control to demonstrate that the reporter construct can be activated (data not shown). Both
PModS(S300) and PModS(C4) activated the SRE construct
(Fig. 2B). The SIE construct was also stimulated by
PModS(S3001and PModS(C4) (Fig. 2B). Interestingly, a construct containing both the SIE and SRE was stimulated to the
a
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sameor lesserdegree asthat containing either element alone.
The entire 400-bp c-fos promoter construct was stimulated
approximately 900% over the control level by PModS(S300)
(data not shown). The control plasmids not containing a
promoter were not influenced by any of the treatments (data
not shown). Purified PModS had a similar action as the
partially purified PModS(S300). This indicates that stimulation of c-fosexpression by PModS is in part mediated through
activation of the SRE and SIE.
To extend these observations, gel retardation/mobility
shift assayswere performed. Nuclear extracts were obtained
from Sertoli cellscultured in the absence(control) or presence
of PModS(S300) or 10% (vol/vol) calf serum as a positive
control. A gel shift with an oligonucleotide to Ott-1 was used
to check the quality of the nuclear extracts (Fig. 3). All extracts
resulted in a similar level of Ott-1 gel shift. To confirm that
c-fos was induced, a gel shift with an AI’1 oligonucleotide
was performed, because the c-fos-jun complex binds to the
AI’1 site. Incubation of the labeled API oligonucleotide with
nuclear extracts of Sertoli cells treated with PModS6300) or
serum resulted in the formation of a DNA-protein complex
with retarded mobility (i.e. gel shift). The observed gel shift
was specific for Al?, because it could be effectively competed by unlabeled AI’1 (Fig. 3). This confirms the induction
of c-fos by both PModS(S300) and serum.
Activation of SRE of the c-fos promoter was also investigated with a gel mobility shift assay using a SRE oligonucleotide (Fig. 4A). PModS(S300) induced a gel shift that was
competed with excessunlabeled SRE. Serum was used as a
positive control and also promoted a gel shift. To assess
whether PModS may promote binding of a ternary complex,
an ETS-SREsequencewas used in a gel shift. The ETS domain
is a 5’-CAGGAT flanking sequenceof the SRE that is needed
for the binding of ETS oncogene-like proteins and is required
for the formation of a ternary complex with the serum responsefactor (SRF) that binds to the SRE. PModS6300) promoted a distinct shift with the ETS-SREthat was not present
in control nontreated cells or in serum-treated cells (Fig. 4Al.
PModS(S300) promoted two distinct gel shifts, whereas serum promoted a diffuse shift below that of PModS(S300).
These gel shifts were displaced with excess unlabeled oligonucleotide (data not shown). Therefore, PModS6300) induced protein binding to the SRE and ETS-SREoligonucleotides. An alternate response element, located 25 bp
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of the c-fos promoter and the
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The designation for the promoter constructs is listed at the left, and
that for the plasmid used at the right. b, Regulation of the c-fos
promoter constructs (CRE, TRE, SIE, and SRE) in Sertoli cells cultured in the absence (control) or presence of PModS(S300) (m) and
PModS(C4) (@. Data are expressed as a percentage of the control and
are presented as the mean t SEM from six different experiments
performed in replicate.
FIG.

OCTI

API

FIG. 3. Cal mobility shift assay with 32P-radiolabeled Ott-1 and APl
oligonucleotides. Nuclear extracts from Sertoli cells cultured in the
absence (C)or presence of PModS(S300) (P) or 10% calf serum (S) were
used. The DNA-protein complexes were electrophoretically
separated
on 5% polyacrylamide gels, then dried and autoradiographed.
The
data are representative of five different experiments.
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FIG. 4. Gelmobility shift assaywith 32P-radiolabeled
SREandETS-

SRE(a), and SIE (b) oligonucleotides.
Nuclearextracts from Sertoli
cellscultured in the absence(0 or presenceof PModS(S300)(P) or
10%calf serum (S) were used.The DNA-protein complexeswere
electrophoreticallyseparatedon 5% polyacrylamidegels, then dried
and autoradiographed.The data are representativeof 10 different
experimentsfor SRE and 5 different experimentsfor SIE.
upstream from the SRE, is the SIE, which is also responsive
to serum. A SIE oligonucleotide gel shift demonstrated that
PModS(S300) promotes a SIE gel shift (Fig. 48). Again, serum
was used as a positive control and promoted the anticipated
gel shift. This SIE gel shift was specific and could be competed by excessunlabeled SIE oligonucleotide. Previously, a
SIE gel shift has been shown to involve three shifts, termed
A, 8, and C. PModS was found to promote all three forms,
with A (lowest) being the predominant (Fig. 4B). The gel shift
data presented confirm the reporter gene experiments previously discussed.Therefore, PModS appears to act through
the SRE and SIE to promote c-fos gene expression.
Tfpromoter

analysis

To determine the location of responseelements within the
Tf promoter that are activated by treatment with PModS,
four CAT constructs containing a 581-bp, 1.6-kb, 2.6-kb, or
3-kb upstream region of the Tf promoter were produced (Fig.
5A). FSH treatment of cells transfected with any of the constructs, except the 2.6- to 1.6-kb Tf PBL-CAT2, termed I-kb
Tf-Tk-CAT, stimulated CAT activity approximately 400%
above control values, confirming that these constructs can be
activated (data not shown; P < 0.01). PModS(S300) treatment
induced activation of the -581-bp, -1.6-kb, and -3-kb Tf
constructs (Fig. 58) to a similar extent. The -2.6-kb Tf construct was stimulated to a greater extent by PModS(S300)
(Fig. 58). Interestingly, the PModS(C4) preparation stimu-

FIG. 5. a, Schematicrepresentationof the Tf promotor-CATcon-

structs andlocationof CRE, SEl, and SE2regions.b, Regulationof
the variousTfpromotor-CATconstructsin Sertolicellsculturedin the
presence
of PModS(S300)
(a) andPModS(C4)(W. Data areexpressed
as a percentageof the value in control nontreatedcells for .each
construct. Data are representativeof three different experiments
performedtwice.
lated primarily the -2.6-kb Tf construct. This indicates that
an enhancer-like activity involved in PModS stimulation of
Tf production is located between -1.6 and -2.6 kb, and a
repressor is located between -2.6 and -3 kb of the promoter.
To extend these observations, the lOOO-bpregion of the promoter between - 1.6 and -2.6 kb was cloned into a Tk-CAT
construct (PBL-CAT2; Fig. 5A), termed lkb Tf-Tk-CAT.
PModS was found to activate this construct, but had only a
slight effect on the control plasmid not containing the I-kb
Tf promoter (Fig. 6). PModS(C4) had an action similar to that
of the partially purified PModS(S300). The plasmid used
contained a minimal thymidine kinase (Tk) promoter with a
TATA box (Tk-CAT) that was required for PModS to activate
this l-kb Tf construct. In the absenceof a minimal promoter
with a TATA box, a similar construct was not activated (data
not shown). Therefore, the ability of PModS to activate the
enhancer elements in this Tf promoter fragment does require
a minimal promoter containing a TATA box.
Although the region between 0 and -581 bp has been
sequenced and mapped, little is currently known about the
distal region of the Tf promoter. Therefore, the exact nature
of these putative upstream regulatory elements is unknown.
To initiate an examination of this region, the entire 2.5-kb
fragment of the Tf promoter between -581 bp and -3 kb was
digested with various restriction enzymes to generate 15
approximately 200-bp fragments. These fragments were
used in gel mobility shift assaysto identify potential PModS-
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To confirm that c-fos does not associatewith the PModSinduced SE1 and SE2 gel shifts, an immunoblot with a c-fos
antiserum of the gel shifts was performed (Fig. 8). Although
a gel shift was detected with both SE1 and SE2, c-foswas not
detected in the DNA-protein complex (Fig. 8). A positive
control API gel shift did contain c-fos in its DNA-protein
complex (Fig. 8). These observations imply that c-fos regulates an intermediate transcription factor(s) that influences
the Tf promoter at SE1 and SE2 (Fig. 9).
Discussion

Constn,c;

Treatment

IKbTf--%&AT
COll@Ol

TIccAT

s300

-

IKbTf-TI-CATs300

c4

FIG. 6. Regulation of a 1-kb fragment of the Tf promoter between
- 1.6 kb and -2.6 kb containing SE1 and SE2 inserted into a Tk-CAT
Dlasmid and termed 1 kb Tf-Tk-CAT. Sertoli cells were cultured in the
absence (C) or presence of PModS(S300) or PModS(C4). The actions
of PModS(S300) on a control Tk-CAT plasmid are also shown. Data
are expressed as a percentage of the value in control nontreated cells
for each construct and are presented as the mean +- SEM from three
different experiments performed twice. ***, Statistically significant
difference from the control (P < 0.01).

responsive regions. Thirteen of these Tf promoter restriction
fragments did not cause a gel shift under control or PModSstimulated conditions (data not shown). Two restriction fragments upstream of the mTf transcriptional start site located
at -2.4 kb, designated SEI, and at -1.9 kb, designated SE2,
did cause a gel shift after PModS stimulation (Fig. 7). The
location of these Sertoli elements (i.e. SE1 and SE2) on the Tf
promoter is diagrammatically shown in Fig. 5A. To determine whether either SE1 or SE2 is a potential APl-binding
site, a competition experiment was carried out with excess
unlabeled AI’1 oligonucleotide. The unlabeled API was not
able to displace the SE1 or SE2 complex. Therefore, the gel
shift appearsnot to be due to a c-fos/jun-binding AI’1 site. The
SE2 fragment was unable to form the DNA-protein complex
with the nuclear extracts of Sertoli cells treated with serum
(Fig. 7). PModS(S300) caused a gel shift with both SE1 and
SE2 that was competed with excessunlabeled oligonucleotide (Fig. 7). ExcessSE2 DNA fragment did not compete for
the SE1 complex, nor did the SE1 compete for the SE2 complex. Thesetwo, apparently distinct, non-APl-containing regions of the Tf promoter appear to be influenced by PModS
actions on Sertoli cells.

FIG. 7. Gel mobility shift assay with
32P-radiolabeled SE1 and SE2 regions
of the Tf promoter. Nuclear extracts
from Sertoli cells cultured in the absence (C) or presence of PModS(S300)
(P) or 10% calf serum (S) were used. The
DNA-protein
complexes were electrophoretically separated on 5% polyacrylamide gels, then dried and autoradiographed.
Incubations
with
excess
unlabeled SEl, SE2, or APl are indicated. The data are representative of
four different experiments.
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The ability of the antisensec-fos oligonucleotide to inhibit
PModSinduced activation of the Tf promoter in Sertoli cells
transfected with the -2.6-kb Tf-CAT reporter construct correlateswith its ability to inhibit Tf protein secretion(6). Thesedata
demonstrated that c-fosis involved in PModS stimulation of Tf
expression by cultured Sertoli cells. To further investigate the
actions of PModS on a molecular level, the effects of PModS on
both the c-fosand Tf promoters were examined.
c-Fos promoter

analysis

The responses of Sertoli cells treated with PModS and
transfected with the reporter constructs containing the different regulatory elements of the c-fos promoter correlated
with previous data obtained on the pharmacology of PModS.
Treatment of cultured Sertoli cells with PModS did not affect
CAMP levels (4), nor was it able to stimulate the reporter
construct with the CRE of the c-fospromoter. The inability of
PModS(S300) treatment to activate the TRE supports the
observation that PModS does not stimulate either calcium
mobilization or phosphoinositide turnover (5), both markers
of protein kinase C activation. The inability of PModS to
influence the TRE and APl (i.e. FAP) site at -290 bp of the
c-fos promoter supports previous findings that PModS actions do not involve calcium mobilization or protein kinase
C activation (5). Only the SRE and SIE were stimulated by
treatment with the PModS(S300) and the highly purified
PModS(C4) preparations. Interestingly, the presenceof both
SRE and SIE was not additive; the effect was the same or
lesserthan that of either element alone. Therefore, the ability
of PModS to induce c-fos expression appears to be through
the activation of SRE and SIE.
The SRE is a 29-bp region within the c-fos promoter. A
67-kilodalton protein has been isolated that binds to the SRE,
the SRF (18). Evidence indicates that the binding of SRF to
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other DNA-binding factors have been identified that interact
with the SRE. The 62-kilodalton SRE direct binding factor
(~62~~~) may be related to the MAPFl protein isolated from
yeast (23). This factor is phosphorylated in vivo and mediates
muscle-specific expression of a-actin. SRE-zinc-binding protein is a member of the C2H2 zinc finger family (24). High
affinity binding is achieved through seven tandemly repeated zinc finger motifs. Rat NFIL-6 is a C/EBP-related
factor whose binding to the SRE is mutually exclusive with
SRF(25). Further analysis of activation of the SRE by PModS
will investigate the potential involvement of known ternary
complex factors, unique ternary complex factors, or novel
SRE-binding proteins.
A second regulatory element that appears to be involved
in PModS stimulation of c-fos is the SIE. It is located 25 bp
upstream of the SRE. The SIE is activated by binding of the
SIF, which has three forms, A, B, and C, and contains a
phosphotyrosine residue (11). Treatment of human epidermoid carcinoma cells with epidermal growth factor and human hepatoma cells with interleukind induces the binding
of SIF-A, whereas treatment of epidermoid cells with interferon-y induced binding of SIF-C (11). This is alsoan example
of the ability of different binding proteins to activate a common regulatory element and stimulate a gene-specific response.PModS induced a SIE gel shift that appears to involve
predominantly SIFtA), but also had detectable SIF(B) and
SIF(C) gel shifts. PModS was also found to activate a SIE
reporter construct. Interestingly, the effects of both the SIE
and SRE were not additive in response to PModS. PModS
appears to influence the c-fos promoter at both the SRE and
SIE. Whether the SIE can compensate and/or regulate the
SRE response remains to be elucidated.
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Gel Shift
SE1

FIG. 8. Immunoblot of an APl, SEl, and SE2 gel mobility shift assay
with a c-fos antiserum. Nuclear extracts from Sertoli cells cultured in
the presence of PModS(S300) (P) or 10% calf serum (S) were used. The
DNA-protein complexes were electrophoresed and separated on 5%
polyacrylamide gels, then either dried and autoradiographed
(Gel
Shift) or electrophoretically blotted to polyvinylidene difluoride membrane and immunoblotted with the c-fos antiserum (Blot). The data
are representative of two experiments.

SRE requires its phosphorylation (19-21). The actions of
PModS require tyrosine phosphorylation events (5). The
DNA-binding domain of SRF is the region necessary for
dimerization and interaction with other proteins to form
ternary complexes (18). Because SRF is ubiquitously expressed, cell-specific activation of the c-fos SRE by SRF appears to be mediated by other ternary complex protein factors. The binding of the ternary complex to the SRE requires
the presenceof the adjoining 5’-side of the SRE-binding site,
the ETS domain binding motif. The protein kinase C-dependent and -independent pathways target different parts of this
ternary complex (22). The expression and/or phosphorylation of these proteins may be involved in mediating cellspecific responsesby the SRE. The SRE gel shift data presented demonstrate that PModS induced a gel shift similar
to that of the positive control with serum treatment. Under
less stringent conditions, a SRE gel shift was detected in
control cells, but a more abundant gel shift was present in
PModS-treated Sertoli cells (data not shown). The identity of
the PModS-induced SRE-binding protein as SRF or other
binding proteins remains to be elucidated. Interestingly,
PModS induced a unique gel shift with the ETS-SREthat was
not observed in control nontreated cells or in serum-treated
cells. Therefore, PModS appears to promote the binding of a
protein complex (e.g.ternary complex) that activates the SRE
within the c-fos promoter. The formation of these ternary
complexes may enable a common regulatory element, such
as the SRE, to have cell-specific activity using ubiquitously
expressedDNA-binding proteins. Alternatively, different or
unique binding factors may be another method by which a
common regulatory element may differentially activate cellspecific gene expression. In support of this proposal, several

Tf promoter

analysis

The downstream effects of PModS-induced c-fos expression were investigated with use of the Tf gene as a differentiated marker of Sertoli cells. The geneexpression of Tf was
inhibited by an antisense c-fos oligonucleotide, indicating
that actions of PModS on the Tf promoter are indeed a downstream c-fosevent. The regions controlling liver-specific transcription of the human Tf gene are composed of multiple
positive and negative acting elements, mostly interacting
with DNA-binding proteins present in either human or rat
liver nuclear extracts (26, 27). The regulation of Tf gene
expression in unstimulated Sertoli cells hasbeen shown to be
distinct from that of liver gene expression (28). Although the
first 581 bp of the human Tf promoter (hTf) and mTf promoter have little similarity, they both contain a CRE site,

P Mod S
Jun
FIG. 9. Schematic of the proposed molecular actions of PModS to regulate
Sertoli cell differentiation.
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which was found to be responsive
to FSH in the current
study. The results with the CAT-mTf
deletion mutants suggest that an enhancer activity is located between
-2.6 and
-1.6 kb for PModS and a repressor between
-2.6 and -3.0
kb. Analysis of restriction
enzyme fragments
of the Tf promoter between
-581 bp and -3kb identified
two distinct
domains, designated
SE1 and SE2, that bind specific nuclear
proteins from Sertoli cells stimulated
with PModS. Interestingly, these Sertoli response elements (i.e. SE1 and SE2) are
located within the apparent enhancer activity between
-2.6
and -1.6 kb of the Tf promoter.
Treatment
with serum also
induced a similar DNA-protein
complex with SEl. The complex formed with SE2 was specific to PModS(S300),
because
treatment with serum or CAMP (data not shown) could not
induce the gel shift. The lack of competition
of SE1 and SE2
with AI’1 suggested that these sites were independent
of APl
and the binding of a c-fos-jun complex. The c-fos immunoblot
confirmed
the absence of c-fos in the SE1 and SE2 DNAprotein complexes.
Therefore,
PModS induced
Tf gene expression may involve both c-fos-dependent
and -independent response elements. It is postulated
that c-fos regulates
the expression
or activities of an intermediate
transcription
factor(s) that subsequently
binds the SE1 and SE2 regions.
The general
mechanism
is currently
proposed,
in that
PModS, through
activation
of the SRE and SIE, induces the
immediate
early response gene c-fos, which then influences
an intermediate
transcription
factor(s) that regulates downstream Sertoli cell differentiated
functions
such as Tf gene
expression.
Future studies will involve elucidation
of the
precise mechanism
by which PModS activates the SRE and
SIE of the c-fos promoter
and Sertoli cell-specific
response
elements (e.g. SE1 and SE2) of the Tf promoter.
The possibility
that Sertoli cell-specific
trans-acting
factors and ternary complex factors as well as unique response elements may be
involved
in the Sertoli cell-specific
activation
of these promoters is being investigated.
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